[1] |
GBD Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories,1990-2019:a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet, 2020, 396(10258):1204-1222. DOI: 10.1016/S0140-6736(20)30925-9.
|
[2] |
|
[3] |
|
[4] |
RANSTAM J, COOK J A, COLLINS G S. Clinical prediction models[J]. Br J Surg, 2016, 103(13):1886. DOI: 10.1002/bjs.10242.
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
黄钜明. "辨质论治"结合慢病管理干预动脉粥样硬化的临床疗效分析[D]. 广州:广州中医药大学,2016.
|
[12] |
北京高血压防治协会,北京糖尿病防治协会,北京慢性病防治与健康教育研究会,等. 基层心血管病综合管理实践指南2020[J]. 中国医学前沿杂志(电子版), 2020, 12(8):1-73. DOI: 10.12037/YXQY.2020.08-01.
|
[13] |
YANG X L, LI J X, HU D S,et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population:the china-PAR project (prediction for ASCVD risk in China)[J]. Circulation, 2016, 134(19):1430-1440. DOI: 10.1161/CIRCULATIONAHA.116.022367.
|
[14] |
RILEY R D, ENSOR J, SNELL K I E,et al. Calculating the sample size required for developing a clinical prediction model[J]. BMJ, 2020, 368:m441. DOI: 10.1136/bmj.m441.
|
[15] |
|
[16] |
STEYERBERG E W. Clinical prediction models:a practical approach to development,validation,and updating[M]. Switzerland:Springer Nature, 2019:37-57. DOI: 10.1007/978-3-030-16399-0.
|
[17] |
HEMANN B A, BIMSON W F, TAYLOR A J. The Framingham Risk Score:an appraisal of its benefits and limitations[J]. Am Heart Hosp J, 2007, 5(2):91-96. DOI: 10.1111/j.1541-9215.2007.06350.x.
|
[18] |
韩泽森,来利红. 冠状动脉粥样硬化性心脏病临床预测模型研究现状概述[J]. 心血管病学进展,2020,41(6):638-641.
|
[19] |
WOLFF R F, MOONS K G M, RILEY R D,et al. PROBAST:a tool to assess the risk of bias and applicability of prediction model studies[J]. Ann Intern Med, 2019, 170(1):51-58. DOI: 10.7326/M18-1376.
|
[20] |
吴锡桂,赖声汉,高红,等. 首都钢铁公司988名男性工人冠心病危险因素的多元分析[J]. 中华心血管病杂志,1983,11(1):28-32.
|
[21] |
LIANG X, WANG Q, JIANG Z Q,et al. Clinical research linking Traditional Chinese Medicine constitution types with diseases:a literature review of 1639 observational studies[J]. Chung I Tsa Chih Ying Wen Pan, 2020, 40(4):690-702. DOI: 10.19852/j.cnki.jtcm.2020.04.019.
|
[22] |
FRANKLIN J. The elements of statistical learning:data mining,inference and prediction[J]. Math Intell, 2005, 27(2):83-85. DOI: 10.1007/BF02985802.
|
[23] |
MAHMOOD S S, LEVY D, VASAN R S,et al. The Framingham Heart Study and the epidemiology of cardiovascular disease:a historical perspective[J]. Lancet, 2014, 383(9921):999-1008. DOI: 10.1016/S0140-6736(13)61752-3.
|
[24] |
QUESADA J A, LOPEZ-PINEDA A, GIL-GUILLÉN V F,et al. Machine learning to predict cardiovascular risk[J]. Int J Clin Pract, 2019, 73(10):e13389. DOI: 10.1111/ijcp.13389.
|
[25] |
WU Y F, FANG Y. Stroke prediction with machine learning methods among older Chinese[J]. Int J Environ Res Public Heath, 2020, 17(6):1828. DOI: 10.3390/ijerph17061828.
|
[26] |
DEBRAY T P, DAMEN J A, SNELL K I,et al. A guide to systematic review and meta-analysis of prediction model performance[J]. BMJ, 2017, 356:i6460. DOI: 10.1136/bmj.i6460.
|
[27] |
MOONS K G, KENGNE A P, WOODWARD M,et al. Risk prediction models:I. Development,internal validation,and assessing the incremental value of a new (bio)marker[J]. Heart, 2012, 98(9):683-690. DOI: 10.1136/heartjnl-2011-301246.
|
[28] |
STEYERBERG E W, PENCINA M J, LINGSMA H F,et al. Assessing the incremental value of diagnostic and prognostic markers:a review and illustration[J]. Eur J Clin Invest, 2012, 42(2):216-228. DOI: 10.1111/j.1365-2362.2011.02562.x.
|
[29] |
|
[30] |
COOK N R. Quantifying the added value of new biomarkers:how and how not[J]. Diagn Progn Res, 2018, 2:14. DOI: 10.1186/s41512-018-0037-2.
|
[31] |
PICKERING J W, ENDRE Z H. New metrics for assessing diagnostic potential of candidate biomarkers[J]. Clin J Am Soc Nephrol, 2012, 7(8):1355-1364. DOI: 10.2215/CJN.09590911.
|